Overview

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

Status:
Completed
Trial end date:
1999-06-01
Target enrollment:
Participant gender:
Summary
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Timolol